Search

Sartorius Stedim Biotech.

Chiusa

SettoreFinanza

213.8 1.76

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

208

Massimo

213.9

Metriche Chiave

By Trading Economics

Entrata

-28M

64M

Vendite

-39M

706M

P/E

Media del settore

79.63

28.186

EPS

0.94

Margine di Profitto

9.097

Dipendenti

10,134

EBITDA

16M

218M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+14.45% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

749M

21B

Apertura precedente

212.04

Chiusura precedente

213.8

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 gen 2026, 18:44 UTC

I principali Market Mover

Agenus Falls After $141 Million Zydus Deal Closes

15 gen 2026, 17:51 UTC

I principali Market Mover

Galaxy Digital Climbs on Texas Data-Center Expansion Approval, Tokenized CLO Issuance

15 gen 2026, 17:25 UTC

I principali Market Mover

ASML Exceeds $500 Billion in Market Value on TSMC's Blockbuster Spending Plans -- Update

15 gen 2026, 23:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

15 gen 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Decline as Enthusiasm Over Election Eases -- Market Talk

15 gen 2026, 23:40 UTC

Discorsi di Mercato

Gold Edges Lower Amid Abating Geopolitical Risks -- Market Talk

15 gen 2026, 23:11 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

15 gen 2026, 23:11 UTC

Discorsi di Mercato

Ryman Healthcare's Resales Remain Key Concern -- Market Talk

15 gen 2026, 23:01 UTC

Discorsi di Mercato

New Zealand's Economy Enters An Upswing -- Market Talk

15 gen 2026, 22:56 UTC

Discorsi di Mercato
Utili

Catalyst Metals Delivers a Beat With Record Gold Output -- Market Talk

15 gen 2026, 22:51 UTC

Discorsi di Mercato

James Hardie's Plant Closures Could Boost Profit by 2%-3% -- Market Talk

15 gen 2026, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Verizon Gets Final California Approval to Secure $9.6 Billion Frontier Deal -- WSJ

15 gen 2026, 21:50 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

15 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Energy & Utilities Roundup: Market Talk

15 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

15 gen 2026, 21:27 UTC

Utili

BlackRock Caps 2025 With Record $14 Trillion in Assets -- 3rd Update

15 gen 2026, 21:15 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Commodities Roundup: Market Talk

15 gen 2026, 21:11 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

15 gen 2026, 21:11 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Canada Antitrust Watchdog Confirms Review of Canadian Energy Deal -- Market Talk

15 gen 2026, 20:10 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Settle Mixed -- Market Talk

15 gen 2026, 20:04 UTC

Utili

These Stocks Are Today's Movers: TSMC, ASML, Goldman, Morgan Stanley, BlackRock, Coinbase, Sandisk, and More -- Barrons.com

15 gen 2026, 20:03 UTC

Discorsi di Mercato

Oil Futures Fall As Iran Risk Premium Fades -- Market Talk

15 gen 2026, 19:26 UTC

Discorsi di Mercato

Silver Closes at Fresh High -- Market Talk

15 gen 2026, 18:29 UTC

I principali Market Mover

Agenus Falls After $141M Zydus Deal Closes

15 gen 2026, 18:20 UTC

Utili

Wall Street Powers Nation's Biggest Banks to Record Year -- WSJ

15 gen 2026, 17:56 UTC

Discorsi di Mercato
Utili

U.S. Bank Results Look Encouraging for European Peers -- Market Talk

15 gen 2026, 17:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Auto & Transport Roundup: Market Talk

15 gen 2026, 17:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

15 gen 2026, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

15 gen 2026, 17:02 UTC

Acquisizioni, Fusioni, Takeovers

KBC Group Completes Acquisition of 98.45% Stake in 365.bank From J&T Finance Group

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

14.45% in crescita

Previsioni per 12 mesi

Media 240 EUR  14.45%

Alto 260 EUR

Basso 210 EUR

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

4

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat